NAD-related treatments have human research, but direct evidence for IV NAD+ as an anti-ageing or wellness treatment is limited. Studies of NAD biology or other NAD-raising compounds should not be treated as proof that IV NAD+ improves energy, cognition or lifespan.
Still uncertain: Durable anti-ageing, energy, cognition, disease-prevention or lifespan benefit from IV NAD+.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
Endogenous dinucleotide coenzyme, not a peptide
Entity type
Metabolite / cofactor
Research focus
Cellular metabolism, ageing and IV wellness research
Human evidence
Direct IV NAD+ human evidence remains sparse. Small infusion studies characterize metabolism/tolerability, while a 2026 systematic review found no eligible IV/IM NAD+ outcome trial demonstrating anti-ageing or wellness efficacy.
Regulatory status
No broad FDA/EMA anti-ageing or wellness indication for IV NAD+ identified.
Main limitations
Durable anti-ageing, energy, cognition, disease-prevention or lifespan benefit from IV NAD+.
Safety
IV administration can produce infusion-related symptoms; long-term clinical benefit/risk is inadequately characterized.
Evidence reviewed
2026-09-18
i
Direct IV NAD+ human evidence remains sparse. Small infusion studies characterize metabolism/tolerability, while a 2026 systematic review found no eligible IV/IM NAD+ outcome trial demonstrating anti-ageing or wellness efficacy.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Oral NR/NMN usually showed biochemical target engagement, but clinically meaningful outcomes were heterogeneous; no eligible IV/IM NAD+ outcome trial for anti-ageing/wellness was identified.
IV administration can produce infusion-related symptoms; long-term clinical benefit/risk is inadequately characterized.
Limited IV data report infusion-related symptoms including GI effects, increased heart rate and chest pressure; long-term benefit-risk is not adequately characterized.
Technical details
Mechanism / biologyCentral redox coenzyme in energy metabolism and substrate for enzymes including sirtuins/PARPs.
Route / formulation boundaryDo not conflate evidence for NAD precursors (NR/NMN) with IV NAD+ itself.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published human IV pilot regimen. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
4outcome records
6linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
